Different goals. Different research pathways.

A triple-receptor agonist still in clinical development—not an approved medicine for general use.

People compare it with semaglutide and tirzepatide because it adds a glucagon pathway to GIP and GLP-1 activity.

Human trials are ongoing. Early results do not establish long-term safety, personal suitability or approval.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A molecule that combines two incretin pathways involved in appetite, glucose response and digestion.

People compare the dual pathway with GLP-1-only options when discussing metabolic outcomes.

Strong human evidence exists for approved branded medicines; that evidence does not validate an unapproved research vial.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A molecule that acts on GLP-1 signalling involved in appetite, digestion and glucose-responsive insulin release.

People compare it with dual- and triple-pathway molecules because it targets one principal incretin receptor.

Strong human evidence exists for approved branded medicines; it cannot be transferred automatically to an unapproved research product.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

GHK is a short peptide; ‘Cu’ indicates the copper ion bound to it.

Interest usually centres on skin appearance, collagen-related signalling, hair and repair research.

Laboratory and some human or topical research exists, but outcomes depend heavily on formulation and use context.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A molecule cells use in energy transfer, DNA-related processes and metabolic signalling.

People explore it in cellular-energy and healthy-ageing discussions, often alongside mitochondrial pathways.

Its biological role is well established, but a product’s route, formulation and claimed outcome need separate evidence.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research peptide whose popularity has moved faster than the available human clinical evidence.

People often compare it for injury or recovery goals and sometimes combine it with TB-500.

Evidence is largely preclinical; robust evidence for safety and benefit in humans remains limited.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A synthetic research fragment discussed in relation to cell movement and repair signalling.

It is often paired online with BPC-157 under a broad ‘recovery stack’ claim.

Direct, high-quality human evidence for marketed TB-500 products is limited.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research peptide that stimulates GHSR signalling; it is not a sleeping aid or automatic muscle-building shortcut.

People discuss it for recovery, sleep and body-composition goals because of its hormone-signalling mechanism.

Human pharmacology research exists, but broad performance claims are not established.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research reference grouped under the weight and metabolic pathway. Confirm the exact identity and selected strength before comparing it.

People usually explore this family in relation to NNMT, NAD, metabolism. These are research interests, not promised benefits.

Evidence quality differs by molecule—from laboratory work to human studies. Ask for the relevant source rather than relying on a seller claim.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research reference grouped under the performance pathway. Confirm the exact identity and selected strength before comparing it.

People usually explore this family in relation to ACE-031, myostatin, activin. These are research interests, not promised benefits.

Evidence quality differs by molecule—from laboratory work to human studies. Ask for the relevant source rather than relying on a seller claim.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research reference grouped under the cellular-health pathway. Confirm the exact identity and selected strength before comparing it.

People usually explore this family in relation to cellular energy, mitochondria, healthy aging. These are research interests, not promised benefits.

Evidence quality differs by molecule—from laboratory work to human studies. Ask for the relevant source rather than relying on a seller claim.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

A research reference grouped under the weight and metabolic pathway. Confirm the exact identity and selected strength before comparing it.

People usually explore this family in relation to adipotide, FTTP, fat. These are research interests, not promised benefits.

Evidence quality differs by molecule—from laboratory work to human studies. Ask for the relevant source rather than relying on a seller claim.

Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.